Home  >  News
you can get e-magazine links on WhatsApp.Click here
Clinical Trials + Font Resize -

UCB announces positive results from phase 3 BE SURE study of bimekizumab as compared to adalimumab in adults with moderate-to-severe plaque psoriasis

Brussels, Belgium
Monday, November 2, 2020, 09:00 Hrs  [IST]

UCB, a global biopharmaceutical company, announced the detailed results of the head-to-head phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate-to-severe plaque psoriasis. These findings were presented for the first time as an oral presentation at the European Academy of Dermatology and Venereology Congress, taking place virtually between October 29-31, 2020.

BE SURE met all primary and secondary ranked endpoints. The co-primary endpoints were at least a 90 per cent improvement in the Psoriasis Area and Severity Index (PASI 90) and Investigator Global Assessment (IGA) of clear or almost clear (IGA 0/1) versus adalimumab at week 16. Secondary endpoints included PASI 90 and IGA 0/1 at weeks 24 and 56, and PASI 100 at weeks 16 and 24.

In BE SURE, patients treated with bimekizumab achieved significantly higher PASI 90, IGA 0/1 and PASI 100 skin clearance rates compared to patients treated with adalimumab at week 16. In patients that started bimekizumab at baseline, response rates were maintained up to a year. Rapid increases in skin clearance rates were seen in patients who switched from adalimumab to bimekizumab at week 24. The safety and efficacy of bimekizumab have not been established, and it is not approved by any regulatory authority worldwide.

“In BE SURE, we saw significantly higher skin clearance rates with bimekizumab compared with one of the most commonly used biologic treatments in psoriasis. The study results also demonstrated the potential benefits of switching patients who are being treated with adalimumab to bimekizumab,” said study investigator, Professor Richard Warren, Salford Royal NHS Foundation Trust and The University of Manchester, United Kingdom.

“These findings from BE SURE, the third positive study in the psoriasis clinical development programme, are further evidence of bimekizumab’s superior depth of response. The results also add to the mounting evidence supporting the potential value of selective inhibition of IL-17F, in addition to IL-17A, for rapid, complete and durable skin clearance, if approved by health authorities. UCB is proud to be developing innovative solutions for psoriasis patients,” said Emmanuel Caeymaex, Executive Vice President Immunology Solutions and Head of US, UCB.

In BE SURE, 86.2 per cent of patients treated with bimekizumab achieved almost clear skin (PASI 90), compared with 47.2 per cent of patients treated with adalimumab at week 16 (p<0.001).1 Additionally, 85.3 per cent of patients treated with bimekizumab achieved IGA 0/1, versus 57.2 per cent of patients treated with adalimumab at week 16 (p<0.001). Significantly more patients treated with bimekizumab achieved complete skin clearance (PASI 100) than those treated with adalimumab: 60.8 per cent versus 23.9 per cent at week 16, and 66.8 per cent versus 29.6 per cent at week 24 (p<0.001 for each comparison).

In the two bimekizumab study arms, PASI 90, PASI 100 and IGA 0/1 response rates were maintained through to week 56. These results were observed across both dosing regimens: bimekizumab every four weeks (Q4W dosing) until week 56, or Q4W dosing for 16 weeks, followed by bimekizumab every eight weeks (Q8W dosing) from week 16 to week 56. In patients treated with adalimumab, response rates for PASI 90, PASI 100 and IGA 0/1 rapidly increased after patients were switched to bimekizumab Q4W dosing at week 24, through to week 56. At week 56, response rates in switched patients were comparable to those who had been treated with bimekizumab throughout the study.

Through weeks 0–24, the active comparator period, treatment emergent adverse events (TEAEs) and serious TEAEs were comparable for patients receiving bimekizumab (71.5 per cent and 1.6 per cent, respectively) and adalimumab (69.8 per cent and 3.1 per cent).1 Through weeks 0–56, 81.4 per cent and 5.1 per cent of patients receiving bimekizumab (including those who switched from adalimumab) experienced TEAEs and serious TEAEs, respectively. The most common TEAEs that were observed for bimekizumab through weeks 0–56 were nasopharyngitis (20.9 per cent), oral candidiasis (16.2 per cent) and upper respiratory tract infection (9.0 per cent). Through week 56, there were no suicidal ideation/behavior, inflammatory bowel disease, or major adverse cardiac events reported in patients treated with bimekizumab.

BE SURE is a phase 3, randomized, double-blind study comparing the efficacy and safety of bimekizumab to adalimumab in adult patients with moderate-to-severe chronic plaque psoriasis. The active-controlled initial treatment period of 24 weeks is followed by a dose-blind maintenance treatment period until week 56. BE SURE enrolled 478 participants with chronic plaque psoriasis for at least six months prior to screening and with an affected body surface area of at least 10 per cent, PASI of at least 12 and IGA score equal to or greater than three on a five-point scale.  

The co-primary endpoints of the study were PASI 90 response (defined as a patient who achieves a 90 percent improvement in PASI) and IGA response (defined as clear or almost clear with at least a two-category improvement relative to baseline) at week 16.

Humira is a registered trademark of AbbVie, Inc.

Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently to IL-17A. Selective inhibition of IL-17F in addition to IL-17A suppresses inflammation to a greater extent than IL-17A inhibition alone.  The safety and efficacy of bimekizumab are being evaluated across multiple disease states as part of a robust clinical programme.

Psoriasis is a common, chronic inflammatory disease with primary involvement of the skin. This skin condition affects men and women of all ages and ethnicities. Psoriasis signs and symptoms can vary but may include red patches of skin covered with silvery scales; dry, cracked skin that may bleed; and thickened, pitted or ridged nails.

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |